Ado-Trastuzumab Emtansine

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
 (A-doh-tras-TOO-zoo-mab em-TAN-seen)

This page contains brief information about ado-trastuzumab emtansine and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA Approval for Ado-Trastuzumab Emtansine

Use in Cancer

Ado-trastuzumab emtansine is approved to treat:

Ado-trastuzumab emtansine is also being studied in the treatment of other types of cancer.

More About Ado-Trastuzumab Emtansine

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Ado-Trastuzumab Emtansine - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Biological Therapies for Cancer - Information about the use of this drug to treat cancer.

Research Results

Clinical Trial Results: For Some Breast Cancers, New Drug May Be Treatment Option - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trials Accepting Patients

Find Clinical Trials for Ado Trastuzumab Emtansine - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted: March 13, 2013
  • Updated: October 23, 2014